JPRN-UMIN000005763已完成未知
A Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Advanced Non-Small Cell (Non squamous cell) Lung Cancer - A Phase II Study of Cisplatin, Pemetrexed and Bevacizumab for Advanced Non-Small Cell (Non squamous cell) Lung Cancer
Japanese Foundation for Cancer Research, the Cancer Institute Hospital0 个研究点目标入组 45 人开始时间: 2011年6月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Subjects with interstitial pneumonia or pulmonary fibrosis. 2)Uncontrolled Active infection 3)No other active malignancies 4)Concurrent use of steroid therapy 5)Subjects with symptomatic brain metastases. 6)have had or require continuous oral administration of hemostat/have had or require injectable administration of hemostat 7)Uncontrolled pleural. 8)Have received radiation therapy to lesions of lung 9)Have a bleeding diathesis 10)Uncontrolled hypertension 11)Any other reason that,in the opinion of the investugator precludes the subject from participating in the study.
研究者
相似试验
已完成
2 期
A phase II study of Cisplatin+Pemetrexed +Bevacizumab for gefitinib refractory NSCLC patients with mutated EGFRon-small cell lung cancer(Non squamous)JPRN-UMIN000012215iigata Lung Cancer Treatment Group28
已完成
2 期
Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer)EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell carcinoma)JPRN-UMIN000003855Departmnent of Thoracic Oncology Kanagawa Cancer Center25
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125